Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are older than 18 years of age
- People who have been diagnosed with Multiple Sclerosis, based on the 2017 McDonald Criteria
- People who have been diagnosed with Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody Disease, or another neuroinflammatory condition other than Multiple Sclerosis
Who may not be able to join:
- People who are unable to have a specific eye scan called Optical Coherence Tomography (OCT) or retinal vessel imaging — for example, due to severe uncontrolled eye movement that prevents focusing with both eyes
- People who have an existing eye condition that could affect the reliability of the eye scan results, such as cataracts, glaucoma, or a history of significant vision correction needs above a certain level (confirm with trial site)
- People who are currently pregnant or breastfeeding
- Healthy volunteers who have a history of significant neurological conditions — such as stroke, certain inflammatory brain conditions, or nerve disorders — that could affect how results are assessed or interpreted
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Athina Papadopoulou, PD Dr. med., University Hospital Basel, Department of Neurology
Phone: +41 61 32 85704
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Occurence of Progression Independent of Relapse Activity (PIRA); Neuroaxonal loss in the retina (as marker of neurodegeneration in the CNS); Neuroinflammation in the retina; Fixation instability (as marker of global neuronal dysfunction in the CNS); Structural changes of the retinal vessels (as marker of systemic microvascular health); (For a subgroup of participants) Functional/perfusional changes of the retinal vessels
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.